Bausch Health
338 hedge funds and large institutions have $4.89B invested in Bausch Health in 2020 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 96 increasing their positions, 122 reducing their positions, and 43 closing their positions.
37% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 43
37% more capital invested
Capital invested by funds: $3.58B → $4.89B (+$1.31B)
26% more call options, than puts
Call options by funds: $206M | Put options by funds: $164M
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
4% more funds holding
Funds holding: 324 → 338 (+14)
1.6% more ownership
Funds ownership: 64.35% → 65.95% (+1.6%)
21% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 122
Top Buyers
| 1 |
IC
Icahn Carl
Sunny Isles Beach,
Florida
|
+$93.9M |
| 2 |
GAM
Goldentree Asset Management
New York
|
+$75.8M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$62.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$36.8M |
| 5 |
GCM
Glenview Capital Management
New York
|
+$27.5M |
Top Sellers
BHC Hedge Fund Activity: Q4 2020 in Review
338 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Bausch Health (BHC) for Q4 2020, worth a combined $4.89B — up 37% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BHC positions and 43 closed out — a net gain of 16 holders — while 96 added to existing stakes and 122 trimmed.
The largest buyer was Icahn Carl, opening a new position worth an estimated $93.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $92.4M.
- 338 institutional investors held Bausch Health (BHC) as of Q4 2020, up from 324 in Q3 2020.
- Funds reported $4.89B of Bausch Health stock for Q4 2020, up 37% quarter-over-quarter.
- 59 funds opened new Bausch Health positions in Q4 2020 and 43 closed out, a net change of +16 holders.
- The largest Bausch Health buyer in Q4 2020 was Icahn Carl, an estimated $93.9M added.
- The largest Bausch Health seller in Q4 2020 was T. Rowe Price Associates, an estimated $92.4M sold.
Based on aggregated 13F filings for Q4 2020.